* Cambridge NeuroScience Inc., of Cambridge, Mass., and the Gladstone Institute of Cardiovascular Disease affiliated with the University of California will collaborate to develop treatments for Alzheimer's disease. The venture will combine the research and drug development capabilities of the two organizations to focus on novel pharmaceuticals designed to inhibit the activity of a form of apolipoprotein E, a molecule that has been widely linked to Alzheimer's disease.
* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., said as a result of an internal company review and meeting with the FDA on Dec. 19, it will initiate an Allervax Cat product trial in the second quarter of 1997, and will modify its development plan to include at least one additional trial prior to a product license application submission of the product to the FDA. ImmuLogic's Phase III data showed only one of four dosing regimens of Allervax Cat: 750 micrograms twice weekly for two weeks, produced a statistically significant benefit compared to placebo. (See BioWorld Today, April 4, 1996, p. 1.)